Key Points
- STERIS VP Julia Madsen sold 5,008 shares on Nov. 21 at an average price of $262 for a total of $1,312,096, reducing her ownership by 31.86% to 10,710 shares, per an SEC filing.
- Recent results beat expectations: STERIS reported $2.47 EPS vs. $2.38 consensus and $1.46B revenue vs. $1.43B, and set FY2026 guidance of $10.15–$10.30 EPS (analysts expect ~9.08 for the current year).
- Dividend and market view: the company declared a $0.63 quarterly dividend (annualized $2.52, yield ~0.9%), and analysts hold a consensus "Moderate Buy" with an average target of $273.50.
STERIS plc (NYSE:STE - Get Free Report) VP Julia Madsen sold 5,008 shares of the firm's stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the transaction, the vice president directly owned 10,710 shares in the company, valued at $2,806,020. The trade was a 31.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
STERIS Price Performance
NYSE STE opened at $267.60 on Wednesday. The company has a 50-day moving average price of $247.61 and a 200-day moving average price of $242.21. STERIS plc has a 52 week low of $200.98 and a 52 week high of $268.60. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $26.26 billion, a P/E ratio of 40.98 and a beta of 1.02.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same quarter last year, the firm posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities research analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.9%. STERIS's payout ratio is presently 36.21%.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on STE. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 14th. Weiss Ratings restated a "buy (b)" rating on shares of STERIS in a research report on Tuesday, October 14th. Finally, Morgan Stanley lifted their price objective on STERIS from $276.00 to $295.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $273.50.
View Our Latest Stock Report on STERIS
Institutional Investors Weigh In On STERIS
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of STERIS by 0.4% in the third quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider's stock valued at $3,022,114,000 after acquiring an additional 50,393 shares in the last quarter. State Street Corp raised its stake in STERIS by 4.0% during the 3rd quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider's stock valued at $1,077,564,000 after purchasing an additional 166,736 shares during the period. Generation Investment Management LLP lifted its holdings in STERIS by 5.4% in the 1st quarter. Generation Investment Management LLP now owns 3,354,545 shares of the medical equipment provider's stock worth $760,308,000 after purchasing an additional 170,392 shares in the last quarter. Geode Capital Management LLC boosted its stake in STERIS by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider's stock worth $592,980,000 after purchasing an additional 46,859 shares during the period. Finally, Orbis Allan Gray Ltd grew its holdings in STERIS by 36.0% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider's stock valued at $504,486,000 after buying an additional 556,088 shares in the last quarter. 94.69% of the stock is owned by institutional investors.
STERIS Company Profile
(
Get Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
